Karyopharm Therapeutics announced that its Phase 3 SENTRY trial abstract has been accepted for a late‑breaking oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, with the presentation scheduled for June 2 2026. The acceptance gives the company a high‑profile platform to present detailed data to the oncology community and potential regulators before the broader market can react.
The SENTRY trial evaluates selinexor in combination with ruxolitinib in patients with myelofibrosis. The study met its primary co‑primary endpoint of a ≥35% reduction in spleen volume, but it did not achieve the secondary co‑primary endpoint of a statistically significant improvement in total symptom score. The mixed outcome underscores the potential of the combination to address a critical unmet need while highlighting the uncertainty that will shape regulatory discussions and commercial strategy.
Karyopharm’s recent financial results provide context for the company’s ability to fund ongoing development. In Q4 2025, total revenue rose 11.8% to $34.1 million, while full‑year 2025 revenue increased modestly to $146.1 million. Net product revenue was $32.1 million in Q4 and $114.9 million for the year, but the company posted net losses of $102.2 million and $196.0 million, respectively. Cash and equivalents stood at $64.1 million, giving the company a liquidity cushion to support the SENTRY trial and future pipeline activities.
CEO Richard Paulson emphasized the strategic importance of the trial. He stated, "2026 has the promise to be a transformative year for Karyopharm and the patient communities that we intend to serve, with top‑line data from our Phase 3 SENTRY trial in myelofibrosis expected in March." He added, "As we enter 2026, Karyopharm is approaching a defining period marked by important upcoming clinical milestones and a continued focus on disciplined execution, positioning the Company at a potential inflection point."
Analysts have responded with mixed views. While RBC Capital maintained an Outperform rating and a $23 price target, Piper Sandler cut its target to $8 and Leerink Partners lowered it to $5, reflecting uncertainty around the symptom‑improvement endpoint. The positive spleen‑volume reduction data, however, has kept some analysts optimistic about the drug’s commercial potential.
The ASCO presentation will allow Karyopharm to discuss the mixed results with regulators and outline a potential supplemental New Drug Application strategy. The outcome of the presentation could influence the company’s commercial trajectory, as the spleen‑volume benefit may support a differentiated positioning, while the missing symptom endpoint will require additional data or post‑marketing commitments to satisfy regulatory and payer expectations.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.